Willow Biosciences Balance Sheet Health
Financial Health criteria checks 4/6
Willow Biosciences has a total shareholder equity of CA$195.0K and total debt of CA$704.0K, which brings its debt-to-equity ratio to 361%. Its total assets and total liabilities are CA$3.2M and CA$3.0M respectively.
Key information
361.0%
Debt to equity ratio
CA$704.00k
Debt
| Interest coverage ratio | n/a |
| Cash | CA$1.18m |
| Equity | CA$195.00k |
| Total liabilities | CA$2.98m |
| Total assets | CA$3.17m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CANS.F's short term assets (CA$1.6M) do not cover its short term liabilities (CA$2.0M).
Long Term Liabilities: CANS.F's short term assets (CA$1.6M) exceed its long term liabilities (CA$1.0M).
Debt to Equity History and Analysis
Debt Level: CANS.F has more cash than its total debt.
Reducing Debt: CANS.F's debt to equity ratio has increased from 0% to 361% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CANS.F has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CANS.F is forecast to have sufficient cash runway for 2 months based on free cash flow estimates, but has since raised additional capital.